Promotions & Moves

Anchiano Therapeutics Names CMO

Kerstein to lead development of DNA-based cancer therapy to treat malignancies in the urinary bladder

David Kerstein, M.D., has been named chief medical officer of Anchiano Therapeutics, a clinical-stage biopharma company focused on novel therapies to treat cancer. Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.

“We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,” said Frank Haluska, president and chief executive officer of Anchiano Therapeutics. “We look forward to his medical leadership.”

“I am eager to contribute to Anchiano’s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,” said Dr. Kerstein.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters